Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.830
+0.150 (8.93%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $311.87 million as of June 18, 2026. Its market cap has increased by 75.00% in one year.
Market Cap
311.87M
Enterprise Value
141.50M
1-Year Change
75.00%
Ranking
Category
Stock Price
$1.83
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $311.87M, an increase of 210.46%. That is a compound annual growth rate of 22.93%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 18, 2026 | 311.87M | 11.22% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Conexeu Sciences | 335.59M |
| Opus Genetics | 331.28M |
| Abeona Therapeutics | 328.86M |
| Silence Therapeutics | 327.33M |
| DiaMedica Therapeutics | 315.22M |
| Fennec Pharmaceuticals | 314.72M |
| Palisade Bio | 313.08M |
| Eledon Pharmaceuticals | 303.03M |